Dihydrotestosterone Levels and Survival in Screening-Detected Prostate Cancer: A 15-yr Follow-up Study

European Urology

Volumn 53, Issue 1, 2008, Pages 106-111

  Kjellman, Anders ^a   Akre, Olof ^a   Norming, Ulf ^a   Törnblom, Magnus ^a   Gustafsson, Ove ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dihydrotestosterone; Prognosis; Prostate cancer

Indexed keywords

ANDROGEN; ANDROSTANOLONE;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CAUSE OF DEATH; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOASSAY; RISK ASSESSMENT;

AGED; DIHYDROTESTOSTERONE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; RISK FACTORS; SURVIVAL RATE; SWEDEN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 36448962342     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.04.063     Document Type: Article

References (24)

1. Stanford J.L., Feng Z., Hamilton A.S., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283 (2000) 354-360
2. Steineck G., Helgesen F., Adolfsson J., et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347 (2002) 790-796
3. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
4. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
5. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
6. Imperato-McGinley J., Gautier T., Zirinsky K., et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 75 (1992) 1022-1026
7. Noble R.L. Sex steroids as a cause of adenocarcinoma of the dorsal prostate in Nb rats, and their influence on the growth of transplants. Oncology 34 (1977) 138-141
8. Huggins C. Studies on prostatic cancer. Arch Surg 43 (1941) 209-223
9. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50 (2006) 935-939
10. Le H., Arnold J.T., McFann K.K., and Blackman M.R. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab 290 (2006) E952-E960
11. Hsing A.W., and Comstock G.W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 2 (1993) 27-32
12. Imamoto T., Suzuki H., Fukasawa S., et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 47 (2005) 308-312
13. Zhu Y.S., Cai L.Q., You X., Cordero J.J., Huang Y., and Imperato-McGinley J. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J Androl 24 (2003) 681-687
14. Burnstein K.L. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95 (2005) 657-669
15. Zhu Y.S. Molecular basis of steroid action in the prostate. Cell Sci 1 (2005) 27-55
16. Friedman A.E. The estradiol-dihydrotestosterone model of prostate cancer. Theor Biol Med Model 2 (2005) 10
17. Weihua Z., Lathe R., Warner M., and Gustafsson J.A. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 99 (2002) 13589-13594
18. Gustafsson O., Norming U., Gustafsson S., Eneroth P., Astrom G., and Nyman C.R. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. Br J Urol 77 (1996) 433-440
19. Labrie F., Belanger A., Cusan L., and Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 82 (1997) 2403-2409
20. Bartsch G., Rittmaster R.S., and Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 37 (2000) 367-380
21. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
22. Akduman B., and Crawford E.D. The PCPT: new findings, new insights, and clinical implications for the prevention of prostate cancer. Eur Urol Suppl 5 (2006) 634-639
23. Guerini V., Sau D., Scaccianoce E., et al. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res 65 (2005) 5445-5453
24. Chang B.L., Zheng S.L., Hawkins G.A., et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 62 (2002) 1784-1789